One thing worth saying clearly: neither is a quick fix
GLP-1 receptor agonists highlight the growing convergence of dermatology and systemic health, reinforcing that what is prescribed for one organ system can have profound and sometimes unexpected implications for the skin and dermatologic diseases, says Adam Friedman, MD, FAAD, Professor and Chair of Dermatology, Residency Program Director, Director of Translational Research, and Director of Supportive Oncodermatology in the Department of Dermatology at George Washington School of Medicine and Health Sciences in Washington, DC
The cost of one vial, and our peptide cost calculator can help you budget is far less than weeks of using degraded medication that provides no benefit
What three scenarios does the post give for true weight gain while still on treatment
UK patients should understand that: Available evidence is largely from Phase 2 studies with relatively short follow-up periods Long-term cardiovascular outcome data are not yet available for either agent Phase 3 trials are ongoing, and results will inform future regulatory submissions to the MHRA UK patients interested in accessing these treatments through clinical trials may wish to consult the NIHR 'Be Part of Research' portal (bepartofresearch.nihr.ac.uk) or ClinicalTrials.gov for current recruitment opportunities
All on-site appointments follow the same medical protocols, sterile standards, and clinical oversight as our in-clinic care
